Antibodies
18 January 2011
MENTRIK Biotech, LLC Acquires Fc Engineered, High Affinity, Fully Humanized Anti-CD20 Antibody (AME-133v)12 January 2011
MEDIMMUNE IN-LICENSES CLINICAL-STAGE ANTI-INFLAMMATORY MONOCLONAL ANTIBODY FROM AMGEN12 January 2011
Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab11 January 2011
Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy10 January 2011
OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R57 January 2011
Amgen and Xencor Enter Option Deal to Co-Develop Xencor’s Novel Antibody for Autoimmune Diseases7 January 2011
Helix BioPharma Corp. Files IND for a U.S. Phase I Clinical Study of Its Cancer Drug Candidate L-DOS477 January 2011
Interim Three Month Data From Ongoing Six Month XOMA 052 Phase 2a Trial Support Safety and Biological Activity6 January 2011
Mercator Therapeutics and X-BODY BioSciences Establish Alliance to Generate Antibody Cancer Therapeutics6 January 2011
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors4 January 2011
Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors4 January 2011
AnaptysBio Receives Milestone Payment from Merck for Successful Delivery of Candidate Antibodies for Therapeutic Use29 December 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE Pediatric Ulcerative Colitis IndicationNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports